Hongchi Jiang

TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.

TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.

TL;DR: Results have provided evidence for clinical investigation of GDC0068, a novel ATP-competitive pan-Akt inhibitor, as the second-line treatment after the failure of sorafenib-medicated molecular targeted therapy for advanced HCC.

TL;DR: This study tested the hypothesis that hypoxia caused by the antiangiogenic effects of sustained sorafenib therapy could induce sorafinib resistance as a cytoprotective adaptive response, thereby limiting sorAFenib efficiency, and found that sustained SorafenIB therapy led to increased intratumor hypoxIA, which was associated with sorafanib sensitivity in HCC subcutaneous mice tumor models.

TL;DR: It is concluded that miR-21 participates in the acquired resistance of sorafenib by suppresing autophagy through the Akt/PTEN pathway and could serve as a therapeutic target for overcoming sorAFenib resistance in the treatment of HCC.